#United States #San Francisco #AusperBio #AHB-137 #HBV Therapies

AusperBio's $120 Million Series C Financing: A Leap Towards Advancing Hepatitis B Therapeutics

San Francisco, August 27, 2026 – AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., collectively known as AusperBio, have announced a noteworthy achievement in their funding journey. The biopharmaceutical company, which specializes in oligonucleotide therapeutics for chronic hepatitis B (CHB) among other diseases, has successfully raised $120 million through a Series C financing round. This completion brings the company’s total funding since 2024 to an impressive $360 million, signaling significant investor confidence in their innovative approaches and development pipeline.

The Series C financing saw participation from notable investors, including a leading strategic investor and new player RA Capital Management, L.P. Existing stakeholders such as HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments also reaffirmed their support. This collective backing not only underscores the potential of AusperBio's lead programs but also highlights the growing interest in advanced hepatitis B therapies.

Advancements in Therapeutic Development

The capital raised will primarily focus on further developing AHB-137, AusperBio's flagship investigational antisense oligonucleotide (ASO) therapy for chronic hepatitis B. The funding will facilitate the progression of AHB-137 into its Phase 3 registrational program, a crucial step toward commercialization readiness. Additionally, these funds will accelerate the advancement of AHB-171, an investigational HBV siRNA candidate designed using the company’s proprietary Au-HALO™ targeted delivery technology.

Dr. Guofeng Cheng, the co-founder and CEO of AusperBio, stated, "This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialization while developing next-generation therapies for CHB." He also expressed gratitude for the sustained confidence shown by existing investors and welcomed RA Capital into the fold.

The potential impact of AHB-137 is underscored by its promising clinical activity demonstrated in previous trials, showing it could serve as an effective backbone therapy aimed at achieving a functional cure for CHB. Dr. Chris Yang, co-founder and CSO, added that their innovative Med-Oligo™ ASO and Au-HALO™ platforms complement each other, enhancing their approach to tackling this serious health issue effectively.

Addressing a Global Health Crisis

The urgency for effective chronic hepatitis B treatments cannot be overstated. According to the World Health Organization, approximately 254 million people are currently living with chronic hepatitis B globally, leading to about 1.1 million deaths each year primarily from cirrhosis and liver cancer. Although existing therapies manage to suppress viral replication, they rarely lead to a functional cure, consequently necessitating prolonged treatment for many.

AusperBio's pioneering efforts with AHB-137 and AHB-171 align with a vital need for innovative treatments capable of providing lasting solutions for patients enduring chronic hepatitis B. Their commitment to advancing oligonucleotide therapeutics signifies a promising frontier in biopharmaceutical development, potentially altering treatment landscapes.

Conclusion

As AusperBio progresses through this critical phase of development, the company's successful Series C financing not only raises hopes for addressing chronic hepatitis B effectively but also positions them as a strong contender in the biopharmaceutical sector. Their advanced research and ongoing clinical trials are set to impact countless patients affected by this significant global health problem. For more details about AusperBio and their innovative research, please visit www.ausperbio.com.